The given literature review discusses the current issue of whether the most effective antiarrhythmic drug cordarone (amiodarone) can be used in obstetrics. This drug is noted to be an iodine-containing agent and belongs to group D, i.e. its use is considered to be contraindicated in pregnant women in both Russian and foreign medicine. Just the same, in clinical practice, there are cases of both life-threatening tachyarrhythmias in pregnant women (during pregnancy and labor) and diverse tachyarrhythmias in the fetus, which lead to heart failure and its antenatal death. The presented literature review systematizes the world experience of practitioners in using cordarone during these emergency situations. It is shown that even when the drug is orally administered for a long time, neonatal hypothyroidism is noted in 17—23%, is easy to treat with medications, and does not result in physical or mental retardation. Single intravenous use of the drug is absolutely safe during pregnancy and lactation. When treating fetal tachyarrhythmias, various authors used the drug both alone and in combination with other antiarrhythmic drugs orally in a pregnant woman or by injection into the umbilical vein with simultaneous fetal ascites evacuation, which was highly effective in restoring heart rhythm and in prolonging pregnancy. The world experience with cordarone cannot be used in the practice of Russian medicine, without revising the concept of a group D drug (possibly, by transferring to group B), the absolute and guaranteed legal protection of medical staff, and a full informed patient consent (first of all, it is necessary to inform that there may be hypothyroidism in a newborn). The alternative to cordarone may be abortion only for medical reasons and/or the impossibility of performing cardiac surgery, or, in case of tachyarrhythmia in the fetus, the high probability of its antenatal death.